The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Healthcare stocks have gotten crushed in 2024, and next year doesn’t look much better. But there are still opportunities for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Discover how Mounjaro the revolutionary weight-loss and diabetes drug by Eli Lilly is set to transform obesity management in ...

Is tech billionaire Elon Musk suffering from type 2 diabetes? Musk recently posted a photo of him dressed as a Santa. Musk ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Just to put into perspective how big a tailwind that weight loss space is for these companies, consider that Lilly's market ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Seemingly overnight, millions of people were taking the medicines, known as GLP-1s, while blockbuster drugs like Ozempic, Wegovy, Mounjaro, and Zepbound brought in billions for pharma companies, and a ...